查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929588

痔瘡膏和注射市場：按產品類型、應用領域、最終用戶和分銷管道分類，全球預測（2026-2032年）

Hemorrhoid Cream & Injector Market by Product Form, Application Site, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年痔瘡膏和注射器市場價值為 4.5284 億美元，預計到 2026 年將成長至 4.8938 億美元，年複合成長率為 7.37%，到 2032 年將達到 7.4521 億美元。

關鍵市場統計數據
基準年 2025 4.5284億美元
預計年份：2026年 4.8938億美元
預測年份 2032 7.4521億美元
複合年成長率 (%) 7.37%

一份策略性入門指南，闡述了影響痔瘡局部用藥和注射劑治療的臨床需求、患者行為變化以及分銷創新。

本執行摘要總結了當前影響痔瘡治療的臨床、商業性和運營趨勢，重點關注外用和注射藥物。治療格局正在發生變化，一方面是患者期望獲得微創、居家治療，另一方面是醫療服務提供者傾向於實證治療方案。同時，通路也在多元化發展，數位藥局和專科診所正在改變患者取得非處方藥和處方藥的方式。因此，相關人員面臨一個複雜的環境，產品差異化、監管政策的清晰性和供應鏈的韌性是關鍵的競爭優勢。

製劑技術的創新、遠端醫療的擴展以及供應鏈的現代化正在匯聚，重新定義產品開發和患者獲取策略。

痔瘡治療方法的研發、給藥和使用方式正在經歷根本性的變革，而這些變化需要相應的策略性應對。製劑科學的進步提高了局部用藥的耐受性和標靶給藥能力，而微創注射療法的創新則拓展了門診治療的選擇。遠端醫療和電子商務同時改變了診斷和購買行為，使患者能夠以前所未有的便利性和匿名性獲得醫療服務和產品。這些趨勢的融合迫使製造商重新思考產品設計、包裝和病患教育。

了解近期關稅如何促使人們重新思考採購方式、改變庫存策略，並加速加強區域製造業的投資。

2025年推出的最新關稅措施對醫用乳膏、塗抹器、注射器及相關組件的整個供應鏈造成了多方面的壓力，對製造商、經銷商和終端用戶的影響各不相同。進口原料和成品關稅的提高推高了依賴全球採購的企業的投入成本，促使它們即時審視供應商合約和物流策略。為此，一些製造商加快了低關稅地區替代供應商的資格認證，而另一些製造商則尋求本地化生產並加強垂直整合，以確保利潤率並減少前置作業時間波動。

透過對產品類型、分銷管道、最終用戶環境和應用領域進行全面細分，建構可行的開發和通路策略。

深入的市場區隔分析揭示了產品和使用模式的顯著差異，每種產品都需要量身定做的商業性策略。根據產品劑型，治療方法可分為乳膏、泡沫劑、凝膠劑、注射器、軟膏和栓劑；乳膏又可區分非處方藥和處方藥；注射器則分為家用和診所用藥。每種劑型都有其特定的配方、監管和患者依從性方面的考量。外用製劑強調耐受性和易用性，而注射劑則需要臨床訓練、無菌包裝和明確的給藥通訊協定。

區域趨勢凸顯了美洲、歐洲、中東和非洲以及亞太地區在監管、分銷和製造方面的不同考量。

區域趨勢為生產商和經銷商帶來了不同的機會和營運限制。在美洲，成熟的零售藥局網路和非處方藥市場促進了消費者對局部用藥創新和通路主導促銷活動的快速接受。監管路徑較為穩定，但仍需重視標籤和安全數據，支付方對成本效益的審查也會影響藥品目錄的收錄和採購決策。相較之下，歐洲、中東和非洲地區（EMEA）的法規結構和報銷環境各不相同，本地臨床證據和與當地經銷商的策略合作往往是進入市場的先決條件。

競爭格局由差異化的製劑技術、臨床證據的產生、策略夥伴關係和卓越營運共同塑造。

痔瘡治療領域的競爭動態取決於各公司在配方科學、臨床開發、生產規模和分銷管道關係方面的差異化能力。主要企業致力於透過提高耐受性、提供緩釋方案和簡化給藥方式來提升產品性能。其他企業則透過提供患者援助計劃和注射操作培訓等服務來脫穎而出，從而推動產品在門診和專科醫療機構的應用。製造商與經銷商之間的策略聯盟和授權協議正成為加速市場准入、擴大地域覆蓋範圍並共用研發和監管風險的重要途徑。

為經營團隊提供可操作、有時限的建議，以協調產品創新、證據產生、彈性供應鏈和數位管道，以實現永續成長。

領導者應優先採取一系列切實可行且有時限的行動，以抓住近期機遇，同時為生態系統的結構性變革做好準備。首先，產品開發應與明確的臨床應用案例保持一致，並直接關注通路和終端用戶的工作流程。例如，在適當情況下，設計以使用者為中心的家用注射器，並確保優先考慮非處方藥定位的乳膏製劑具有良好的耐受性。其次，投資於真實世界證據項目和臨床醫生教育舉措，以支持產品在門診和專科機構的應用，並解決支付方對臨床和經濟價值的擔憂。

為確保研究結果的可靠性和可操作性，調查方法包括：整合一手訪談、臨床證據審查、通路分析和情境規劃。

本報告整合了一手和二手研究，全面展現了臨床、商業性和營運方面的動態。一手研究包括對臨床醫生、採購主管和通路夥伴進行結構化訪談，以及對門診中心和專科診所進行現場考察，以觀察工作流程和產品使用情況。二手研究包括對監管指南、臨床文獻和產品標籤進行系統性回顧，以驗證相關聲明和安全性數據。分銷實務和採購行為的資料則透過交易分析和經銷商訪談結合的方式取得，以檢驗通路假設。

總之，綜合分析強調了整合臨床差異化、強大的營運結構和分銷策略的必要性，以將創新轉化為永續的優勢。

總之，痔瘡治療市場正處於關鍵轉折點，臨床創新、不斷演變的通路和貿易趨勢的交匯點既帶來了機遇，也帶來了風險。外用製劑和注射製劑的研發和商業化路徑截然不同，需要針對不同產品製定最佳化的實證策略和通路。受近期貿易措施的影響，供應鏈韌性和區域生產考量已成為策略重點。積極應對這些營運挑戰的企業將更有利於確保產品供應並保持競爭優勢。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的痔瘡膏和注射市場

  • 奶油
    • 非處方藥
    • 處方箋
  • 形式
  • 凝膠
  • 注射器
    • 家用
    • 醫療機構內部
  • 軟膏
  • 栓劑

9. 按應用領域分類的痔瘡膏和注射市場

  • 外痔
  • 內痔
  • 混合型痔瘡

第10章 依最終用戶分類的痔瘡膏和注射市場

  • 門診手術中心
  • 居家醫療
  • 醫院和診所
  • 專科診所

第11章 痔瘡膏和注射市場（依分銷管道分類）

  • 藥局
  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 超級市場和大賣場

第12章 痔瘡膏和注射市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 痔瘡膏及注射市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國痔瘡膏及注射市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國痔瘡膏及注射市場

第16章 中國痔瘡膏及注射市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Almirall, SA
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Church & Dwight Co., Inc.
  • Cipla Limited
  • Endo International plc
  • FDC Limited
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson Consumer Inc.
  • LEO Pharma A/S
  • Medexus Pharmaceuticals Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Procter & Gamble Company
  • Reckitt Benckiser Group plc
  • Sanofi SA
  • Sanofi-Aventis US LLC
  • Sharpe Holdings Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Cadila
Product Code: MRR-0A3806951837

The Hemorrhoid Cream & Injector Market was valued at USD 452.84 million in 2025 and is projected to grow to USD 489.38 million in 2026, with a CAGR of 7.37%, reaching USD 745.21 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 452.84 million
Estimated Year [2026] USD 489.38 million
Forecast Year [2032] USD 745.21 million
CAGR (%) 7.37%

A strategic primer that frames clinical imperatives, evolving patient behaviors, and distribution innovations shaping topical and injectable hemorrhoid therapies

This executive summary synthesizes current clinical, commercial, and operational dynamics shaping hemorrhoid therapies, focusing on topical formulations and injectables. The treatment landscape is evolving as patient expectations for minimally invasive, at-home care intersect with provider preferences for evidence-based procedural options. At the same time, distribution channels are diversifying, with digital pharmacies and specialty clinics altering how patients access both over-the-counter and prescription treatments. Stakeholders therefore face a complex environment in which product differentiation, regulatory clarity, and supply chain resilience have become primary competitive levers.

Clinicians increasingly emphasize patient comfort and rapid symptom relief, driving demand for products that balance efficacy with tolerability. Concurrently, innovation in delivery mechanisms-ranging from advanced topical formulations to office-based injectables-has broadened therapeutic choices and introduced new commercial pathways. Payers and procurement teams are attentive to cost-effectiveness and real-world outcomes, which has elevated the importance of clinical evidence and post-market surveillance. As a result, manufacturers and distributors must align product development, clinical programs, and go-to-market strategies to meet evolving stakeholder expectations while navigating regulatory and trade dynamics.

How formulation breakthroughs, telehealth expansion, and supply chain modernization are converging to redefine product development and patient access strategies

Fundamental shifts are reshaping how hemorrhoid treatments are developed, delivered, and consumed, and these shifts demand strategic response. Advances in formulation science have improved the tolerability and targeted delivery of topical therapies, while innovations in minimally invasive injectables have expanded outpatient therapeutic options. Telehealth and e-commerce have simultaneously changed diagnostic and purchasing behaviors, enabling patients to obtain care and products with unprecedented convenience and anonymity. These converging trends are prompting manufacturers to rethink product design, packaging, and patient education.

Moreover, regulatory emphasis on real-world evidence and safety monitoring has intensified, encouraging companies to invest in post-approval studies and patient support programs. Supply chain modernization, including greater reliance on regional manufacturing and digital inventory management, is mitigating some distribution risks but also introducing new operational requirements. Taken together, these transformative shifts are accelerating the need for integrated strategies that connect clinical value propositions to scalable distribution models and resilient manufacturing footprints.

Illustrating how recent tariff measures have driven sourcing realignment, inventory strategy changes, and accelerated investments in regional manufacturing resilience

Recent tariff actions introduced in 2025 have exerted multi-dimensional pressures across the supply chain for medical creams, applicators, syringes, and related components, affecting manufacturers, distributors, and end users in different ways. Increased duties on imported raw materials and finished goods have raised input costs for companies that rely on global sourcing, prompting immediate reassessments of supplier contracts and logistics strategies. In response, some manufacturers accelerated qualification of alternate suppliers in lower-tariff jurisdictions, while others pursued localized production or greater vertical integration to insulate margins and reduce lead-time volatility.

The cumulative impact extended beyond direct cost increases; it also reshaped inventory policies and capital allocation decisions. Distributors recalibrated safety stock levels and prioritized product lines with the most stable supply economics, even as demand patterns shifted toward over-the-counter solutions and at-home care. Healthcare providers and payers evaluated the trade-offs between domestic sourcing premiums and continuity of supply, often favoring predictable access for clinically critical items. Consequently, tariffs catalyzed strategic shifts that emphasized supply chain transparency, scenario planning, and targeted investments in automation and onshore manufacturing capacity to mitigate future trade-related disruptions.

Comprehensive segmentation that links product forms, distribution channels, end user environments, and application sites to actionable development and channel strategies

Insightful segmentation analysis reveals distinct product and usage patterns that require tailored commercial approaches. Based on product form, therapies span Cream, Foam, Gel, Injector, Ointment, and Suppository, with creams differentiated between Over The Counter and Prescription variants and injectors offering At-Home and In-Clinic applications. Each form carries specific formulation, regulatory, and patient adherence considerations: topical options emphasize tolerability and ease of use, while injectables demand clinical training, sterile packaging, and clear administration protocols.

Channel dynamics reflect varied patient touchpoints and purchasing behaviors. Based on distribution channel, treatments flow through Drug Store, Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Supermarket & Hypermarket outlets, each with different stocking practices, reimbursement interfaces, and patient education opportunities. End users likewise diverge in needs and procurement practices; based on end user, care is delivered across Ambulatory Surgical Centers, Home Care, Hospitals & Clinics, and Specialty Clinics, where clinical staffing and procedural volumes influence product selection. Finally, application site considerations dictate clinical positioning; based on application site, therapies address External Hemorrhoids, Internal Hemorrhoids, and Mixed Hemorrhoids, requiring distinct claims, formulation strategies, and supporting evidence. Integrating these segmentation lenses enables stakeholders to prioritize R&D investment, channel strategy, and evidence generation that align with both clinical use cases and commercial pathways.

Regional dynamics that highlight distinct regulatory, distribution, and manufacturing considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics create differentiated opportunities and operational constraints for manufacturers and distributors. In the Americas, established retail pharmacy networks and a mature over-the-counter culture favor rapid consumer adoption of topical innovations and channel-led promotional initiatives. Regulatory pathways are stable but require attention to labeling and safety data, and payer scrutiny on cost-effectiveness can influence formulary placement and procurement decisions. In contrast, Europe, Middle East & Africa present a mosaic of regulatory frameworks and reimbursement environments, where localized clinical evidence and strategic partnerships with regional distributors are often prerequisites for penetration.

Meanwhile, Asia-Pacific demonstrates strong manufacturing capacity and an expanding base of outpatient clinics and e-commerce adoption, which creates both sourcing advantages and competitive pressure. Rapid urbanization and growing demand for minimally invasive outpatient procedures have spurred interest in injectable therapies in several markets across the region. As a result, companies must balance global development priorities with region-specific regulatory compliance, channel strategy, and supply chain design to realize commercial potential while ensuring operational resilience.

Competitive landscape shaped by differentiated formulation capabilities, clinical evidence generation, strategic partnerships, and operational excellence

Competitive dynamics in the hemorrhoid therapy space are shaped by differentiated capabilities in formulation science, clinical development, manufacturing scale, and channel relationships. Leading players focus on enhancing product profiles through improved tolerability, extended-release options, and delivery systems that simplify administration. Others concentrate on service differentiation, such as patient support programs and clinician training for injectable procedures, to drive adoption in outpatient and specialty settings. Strategic partnerships and licensing agreements between manufacturers and distributors have emerged as critical mechanisms to accelerate market entry and expand geographic reach while sharing developmental and regulatory risks.

Additionally, investment in regulatory affairs and real-world evidence collection is a common theme among high-performing companies. Organizations that rapidly generate robust post-market safety and efficacy data can strengthen payer dialogues and clinician confidence, thereby improving utilization patterns. Operationally, firms that optimize manufacturing flexibility and implement strong quality systems mitigate supply disruptions and enhance their attractiveness as long-term suppliers to institutional purchasers and retail chains.

Actionable, time-bound recommendations for executives to align product innovation, evidence generation, resilient supply chains, and digital channels for sustainable growth

Leaders should prioritize a set of pragmatic, time-bound actions to capture near-term opportunities while preparing for structural shifts in the ecosystem. First, align product development with clear clinical use cases that map directly to distribution channels and end-user workflows; for example, design injectors with user-centric features for at-home administration where appropriate, and ensure cream formulations emphasize tolerability for OTC positioning. Second, invest in real-world evidence programs and clinician education initiatives that support adoption in ambulatory and specialty settings and address payer concerns about clinical and economic value.

Third, enhance supply chain resilience by diversifying supplier networks, qualifying regional manufacturing partners, and adopting inventory optimization tools that reduce lead-time risks. Fourth, adapt commercial models to leverage digital channels and telehealth partnerships that improve access and patient engagement. Finally, establish cross-functional teams that integrate regulatory, commercial, and operations expertise to accelerate launch readiness and respond quickly to trade or policy changes. Together, these recommendations will help organizations navigate near-term headwinds while building capabilities for sustained competitiveness.

Methodological approach integrating primary interviews, clinical evidence review, distribution analysis, and scenario planning to ensure robust actionable insights

This report synthesizes primary and secondary research to develop a comprehensive view of clinical, commercial, and operational dynamics. Primary research comprised structured interviews with clinicians, procurement leaders, and channel partners, supplemented by site visits to ambulatory centers and specialty clinics to observe workflow and product usage. Secondary research included a systematic review of regulatory guidance, clinical literature, and product labeling to triangulate claims and safety profiles. Data on distribution practices and purchasing behaviors were derived from a combination of transactional analyses and distributor interviews to validate channel assumptions.

Analytical methods included segmentation mapping across product form, channel, end user, and application site to identify demand drivers and operational constraints. Scenario analysis assessed the implications of trade actions, supply disruptions, and regulatory shifts on sourcing and inventory strategies. Where feasible, real-world evidence and post-market surveillance data were reviewed to corroborate clinical performance narratives. Limitations include variability in regional reporting standards and the evolving nature of telehealth adoption, which may affect near-term distribution patterns; nevertheless, the methodology emphasizes triangulation and stakeholder validation to ensure robust, actionable insight.

Concluding synthesis that underscores the necessity of integrating clinical differentiation, resilient operations, and channel strategies to convert innovation into lasting advantage

In conclusion, the hemorrhoid therapy landscape is at an inflection point where clinical innovation, channel evolution, and trade dynamics intersect to create both opportunity and risk. Topical formulations and injectables each present distinct development and commercialization pathways that require tailored evidence strategies and channel alignment. Supply chain resilience and regional manufacturing considerations have become strategic priorities in the wake of recent trade actions, and companies that proactively address these operational imperatives will be better positioned to sustain product availability and competitive advantage.

Ultimately, success will hinge on the ability to integrate clinical value propositions with pragmatic distribution strategies and robust evidence generation. Organizations that invest in patient-centered design, clinician engagement, and diversified sourcing while leveraging digital channels for patient acquisition and education will likely lead the next wave of adoption. Clear coordination across R&D, regulatory, supply chain, and commercial functions will be essential to translate innovation into measurable clinical impact and durable business outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hemorrhoid Cream & Injector Market, by Product Form

  • 8.1. Cream
    • 8.1.1. Over The Counter
    • 8.1.2. Prescription
  • 8.2. Foam
  • 8.3. Gel
  • 8.4. Injector
    • 8.4.1. At-Home
    • 8.4.2. In-Clinic
  • 8.5. Ointment
  • 8.6. Suppository

9. Hemorrhoid Cream & Injector Market, by Application Site

  • 9.1. External Hemorrhoids
  • 9.2. Internal Hemorrhoids
  • 9.3. Mixed Hemorrhoids

10. Hemorrhoid Cream & Injector Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Home Care
  • 10.3. Hospitals & Clinics
  • 10.4. Specialty Clinics

11. Hemorrhoid Cream & Injector Market, by Distribution Channel

  • 11.1. Drug Store
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy
  • 11.5. Supermarket & Hypermarket

12. Hemorrhoid Cream & Injector Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hemorrhoid Cream & Injector Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hemorrhoid Cream & Injector Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Hemorrhoid Cream & Injector Market

16. China Hemorrhoid Cream & Injector Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Almirall, S.A.
  • 17.6. Aurobindo Pharma Limited
  • 17.7. Bausch Health Companies Inc.
  • 17.8. Bayer AG
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Church & Dwight Co., Inc.
  • 17.11. Cipla Limited
  • 17.12. Endo International plc
  • 17.13. FDC Limited
  • 17.14. GlaxoSmithKline plc
  • 17.15. Glenmark Pharmaceuticals Ltd.
  • 17.16. Johnson & Johnson Consumer Inc.
  • 17.17. LEO Pharma A/S
  • 17.18. Medexus Pharmaceuticals Inc.
  • 17.19. Mylan N.V.
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc.
  • 17.22. Procter & Gamble Company
  • 17.23. Reckitt Benckiser Group plc
  • 17.24. Sanofi S.A.
  • 17.25. Sanofi-Aventis U.S. LLC
  • 17.26. Sharpe Holdings Inc.
  • 17.27. Sun Pharmaceutical Industries Ltd.
  • 17.28. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HEMORRHOID CREAM & INJECTOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HEMORRHOID CREAM & INJECTOR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY FOAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY FOAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY FOAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY AT-HOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY AT-HOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY AT-HOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY IN-CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY IN-CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY IN-CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SUPPOSITORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SUPPOSITORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SUPPOSITORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY EXTERNAL HEMORRHOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY EXTERNAL HEMORRHOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY EXTERNAL HEMORRHOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INTERNAL HEMORRHOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INTERNAL HEMORRHOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INTERNAL HEMORRHOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY MIXED HEMORRHOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY MIXED HEMORRHOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY MIXED HEMORRHOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DRUG STORE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DRUG STORE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SUPERMARKET & HYPERMARKET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SUPERMARKET & HYPERMARKET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SUPERMARKET & HYPERMARKET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GCC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 141. GCC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 142. GCC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 143. GCC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. G7 HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 162. G7 HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 163. G7 HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 164. G7 HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. G7 HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. NATO HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 169. NATO HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 170. NATO HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 171. NATO HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES HEMORRHOID CREAM & INJECTOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA HEMORRHOID CREAM & INJECTOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY CREAM, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA HEMORRHOID CREAM & INJECTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)